Literature DB >> 30205005

Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.

Timothy R Hodges, Jason R Abbott, Andrew J Little, Dhruba Sarkar, James M Salovich, Jennifer E Howes, Denis T Akan, Jiqing Sai, Allison L Arnold, Carrie Browning, Michael C Burns, Tammy Sobolik, Qi Sun, Yugandhar Beesetty, Jesse A Coker, Dirk Scharn1, Heinz Stadtmueller1, Olivia W Rossanese, Jason Phan, Alex G Waterson2, Darryl B McConnell1, Stephen W Fesik2.   

Abstract

Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in ∼30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series of benzimidazole-derived SOS1 agonists. Using structure-guided design, we discovered small molecules that increase nucleotide exchange on RAS in vitro at submicromolar concentrations, bind to SOS1 with low double-digit nanomolar affinity, rapidly enhance cellular RAS-GTP levels, and invoke biphasic signaling changes in phosphorylation of ERK 1/2. These compounds represent the most potent series of SOS1 agonists reported to date.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30205005      PMCID: PMC8314423          DOI: 10.1021/acs.jmedchem.8b01108

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK.

Authors:  Yuji Kamioka; Shuhei Yasuda; Yoshihisa Fujita; Kazuhiro Aoki; Michiyuki Matsuda
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

Review 2.  The influence of drug-like concepts on decision-making in medicinal chemistry.

Authors:  Paul D Leeson; Brian Springthorpe
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

Review 3.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

4.  Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

Authors:  Carlotta Petti; Alessandra Molla; Claudia Vegetti; Soldano Ferrone; Andrea Anichini; Marialuisa Sensi
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

5.  Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.

Authors:  Elizaveta S Leshchiner; Andrey Parkhitko; Gregory H Bird; James Luccarelli; Joseph A Bellairs; Silvia Escudero; Kwadwo Opoku-Nsiah; Marina Godes; Norbert Perrimon; Loren D Walensky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

Review 6.  Small-molecule modulation of Ras signaling.

Authors:  Jochen Spiegel; Philipp M Cromm; Gunther Zimmermann; Tom N Grossmann; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2014-06-15       Impact factor: 15.040

7.  A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A.

Authors:  Elaine M Souza-Fagundes; Andreas O Frank; Michael D Feldkamp; Daniel C Dorset; Walter J Chazin; Olivia W Rossanese; Edward T Olejniczak; Stephen W Fesik
Journal:  Anal Biochem       Date:  2011-12-01       Impact factor: 3.365

8.  Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

Authors:  S Rao; D Cunningham; A de Gramont; W Scheithauer; M Smakal; Y Humblet; G Kourteva; T Iveson; T Andre; J Dostalova; A Illes; R Belly; J J Perez-Ruixo; Y C Park; P A Palmer
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

9.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

10.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

Authors:  Qi Sun; Jason P Burke; Jason Phan; Michael C Burns; Edward T Olejniczak; Alex G Waterson; Taekyu Lee; Olivia W Rossanese; Stephen W Fesik
Journal:  Angew Chem Int Ed Engl       Date:  2012-05-08       Impact factor: 15.336

View more
  7 in total

Review 1.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist.

Authors:  Sébastien L Degorce; Michael S Bodnarchuk; James S Scott
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

3.  Conformations and binding pockets of HRas and its guanine nucleotide exchange factors complexes in the guanosine triphosphate exchange process.

Authors:  Yuqing Xiong; Juan Zeng; Fei Xia; Qiang Cui; Xianming Deng; Xin Xu
Journal:  J Comput Chem       Date:  2022-03-24       Impact factor: 3.672

Review 4.  Structural Insights into the Regulation Mechanism of Small GTPases by GEFs.

Authors:  Sachiko Toma-Fukai; Toshiyuki Shimizu
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

Review 5.  Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.

Authors:  Kinga Nyíri; Gergely Koppány; Beáta G Vértessy
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

6.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

7.  Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen.

Authors:  Jenna Giubilaro; Doris A Schuetz; Tomasz M Stepniewski; Yoon Namkung; Etienne Khoury; Mónica Lara-Márquez; Shirley Campbell; Alexandre Beautrait; Sylvain Armando; Olivier Radresa; Jean Duchaine; Nathalie Lamarche-Vane; Audrey Claing; Jana Selent; Michel Bouvier; Anne Marinier; Stéphane A Laporte
Journal:  Nat Commun       Date:  2021-08-03       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.